SynAct is progressing with the recruitment of patients to its Phase 2b ADVANCE study in patients with newly diagnosed severe rheumatoid arthritis (RA) and is accelerating its plans to expand the use of resomelagon into other indications. Please join the CMD to hear about SynAct’s efforts and path forward.

Agenda
15.00 Introduction by Chairman – Anders Kronborg
15.10 Corporate Update – Jeppe Øvlesen, CEO
15:25 Resomelagon
- Induce inflammatory resolution though biased agonism at the melanocortin system
- Parallel development tracks
15:45 Inflammatory and Autoimmune diseases
- Positioning and development in Rheumatoid Arthritis
- The Advance study
- New opportunities in Rheumatic diseases
16:15 Host-directed therapy in Viral infections – Professor Mauro Teixeira
- Preclinical update
- The RESOVIR-2 study in Dengue
16:45 The TXP program
16:55 Wrap-up and summary – Jeppe Øvlesen, CEO
17:00 Mingle and drinks

When: June 4, 2025, from 15:00-17:00 CEST
Location: Investor Studios, Hötorgsskrapan 3
Address: Sveavägen 9 or Mäster Samuelsgatan 42 or Sergelgatan 8 – 10, Floor 7
Additional information:
If you enter the building via Sveavägen 9 or Sergelgatan 8 – 10, choose the escalator, turn to the left after entering the next floor and choose the elevator in front of you (floor 7) 
If you enter the building via Mäster Samuelsgatan 42, go straight ahead and pass the reception and continue towards the elevators you see in front of you (floor 7).

Follow the broadcast live here:
 https://www.youtube.com/live/COqFXRFQP0Q?si=eFOOty9RtXaBSMri

The Capital Markets Day will be held in English. Presentation material will be available on SynAct’s website afterwards.

Registration for the event is made by mailing investor.relations@synactpharma.com